Cytokinetics Revenue and Competitors
Estimated Revenue & Valuation
- Cytokinetics's estimated annual revenue is currently $21.6M per year.
- Cytokinetics's estimated revenue per employee is $47,889
- Cytokinetics's total funding is $1.1B.
- Cytokinetics's current valuation is $2.8B. (January 2022)
- Cytokinetics has 450 Employees.
- Cytokinetics grew their employee count by 45% last year.
Cytokinetics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Cytokinetics?
We are a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. A number of commonly used drugs and a growing body of research validate the role that the cytoskeleton plays in a wide array of human diseases. Our focus on the cytoskeleton enables us to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases. We have developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. We believe that our approach enhances the speed, efficiency and yield of our drug discovery and development process by accurately and rapidly identifying drug candidates with attractive properties. Our approach has yielded two drug candidates for the treatment of cancer, a drug candidate for the treatment of acute congestive heart failure and more than ten other research programs. Our most advanced drug candidate, SB-715992, is the subject of a broad Phase II clinical trials program designed to evaluate its effectiveness in many different types of cancer. An investigational new drug application, or IND, was filed with the U.S. Food and Drug Administration, or FDA, in 2003 for our second cancer drug candidate, SB-743921, which we expect will enter Phase I clinical development in early 2004. SB-715992 and SB-743921 are being developed through our strategic alliance with GlaxoSmithKline. In addition, we expect to initiate Phase I clinical development for a drug candidate, CK-1213296, for the treatment of acute congestive heart failure in the second half of 2004.keywords:Pharmaceuticals
Number of Employees
Employee Growth %
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators...
Cytokinetics focuses on the mechanics of muscle biology, utilizing its research and development platform to aid in developing drugs that combat...
Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show...
Shares of Cytokinetics opened down 7.3 percent Monday morning, but had risen nearly 9 percent by the early afternoon. The drug is being developed in partnership with Japan-based Astellas. The company nevertheless said a post-hoc analysis pooling together the three dose levels – 150mg, 300mg and ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|